This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care
by Zacks Equity Research
Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.
Here's Why You Should Retain Phibro (PAHC) Stock For Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) owing to the robust performances by its Animal Health and Mineral Health segments.
The Zacks Analyst Blog Highlights Splunk, Vertex Pharmaceuticals, Henry Schein, Jack Henry & Associates, and Check Point Software Technologies
by Zacks Equity Research
Splunk, Vertex Pharmaceuticals, Henry Schein, Jack Henry & Associates, and Check Point Software Technologies are part of Top Analyst Blog.
Integer Holdings' (ITGR) Latest Buyout to Expand Its Footprint
by Zacks Equity Research
Integer Holdings' (ITGR) buyout of Aran Biomedical is set to expand its presence in high-growth markets as well as enhance its product offerings.
Masimo's (MASI) Sound United Buyout to Boost Product Portfolio
by Zacks Equity Research
Masimo's (MASI) completion of Sound United's buyout to help enhance the former's extended portfolio of hospital and home medical technology solutions.
Top 5 High-Flying Nasdaq Stocks Amid Index's YTD Meltdown
by Nalak Das
We have narrowed our search to five Nasdaq listed stocks that have witnessed double-digit rally year to date. These are: VRTX, SPLK, HSIC, CHKP and JKHY.
Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.
Quidel Corporation (QDEL) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.
Abiomed (ABMD) Announces Successful Usage of Impella in Japan
by Zacks Equity Research
Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
AmerisourceBergen's (ABC) Venture Capital Fund to Aid Healthcare
by Zacks Equity Research
AmerisourceBergen's (ABC) new corporate venture capital fund to help emerging healthcare startup companies change healthcare for people and animals globally.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.
PerkinElmer (PKI) Boosts In Vivo Imaging Profile With New System
by Zacks Equity Research
PerkinElmer's (PKI) launch of the Vega imaging system is likely to help the company expand its in vivo imaging portfolio.
PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities
by Zacks Equity Research
PerkinElmer (PKI) launches ready-to-use HTRF and AlphaLISA no-wash assay kits to quickly identify and quantify CHO HCP impurities.
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
by Zacks Equity Research
Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time
by Zacks Equity Research
Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.
DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management
by Zacks Equity Research
DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
by Zacks Equity Research
Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.